
Loading, please wait...

Loading, please wait...

Central nervous system (CNS) diseases often result in irreversible damage because inflammatory factors trigger chronic injuries within complex neural architectures. Unfortunately, the blood-brain barrier (BBB) naturally prevents many traditional drugs from reaching their intended targets. To address this medical challenge, researchers are exploring single-atom nanozymes (SAzymes) as a revolutionary therapeutic platform. These advanced materials feature atomic-level dispersion of active sites, ensuring maximum atom utilization and highly tunable chemical environments.
Compared to traditional nanozymes, these single-atom platforms exhibit significantly higher catalytic activity. Furthermore, they allow scientists to decipher complex structure-activity relationships more effectively than bulk materials. Because of their high tunability, researchers can optimize these active sites for specific neurological applications. Therefore, these materials—which include carbon-based structures, metal-organic frameworks (MOFs), and metal oxides—offer a more precise approach to drug design.
Recent evidence highlights the powerful anti-inflammatory and antibacterial properties of these single-atom systems. Consequently, clinicians are investigating the role of various SAzymes in treating brain injury, stroke, and neurodegenerative diseases. Additionally, these nanozymes serve as vital tools for biological monitoring and long-term neuroprotection. By leveraging their unique atomic structures, scientists can now propose novel therapeutic strategies that were previously impossible to achieve with conventional pharmacology.
While the potential for SAzymes is vast, several key challenges remain regarding their clinical translation. Researchers must still conduct in-depth analyses of long-term toxicity and large-scale synthesis methods. However, the superior catalytic properties and the ability to cross biological barriers suggest that single-atom nanozymes will remain a hot topic in neurological research for years to come.
SAzymes are a class of nanomaterials where the active metal sites are atomically dispersed on a support, providing high catalytic efficiency similar to natural enzymes.
They offer superior anti-inflammatory and antibacterial properties and can be engineered to cross the blood-brain barrier more effectively than many standard drugs.
Common materials include carbon-based nanostructures, metal-organic frameworks (MOFs), metal oxides, and metal sulfides, each offering unique coordination environments for the active metal atoms.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.
References
Yang Y et al. Single-atom nanozymes: a new platform for central nervous system disease research. Chem Commun (Camb). 2026 Feb 10. doi: 10.1039/d6cc00053c. PMID: 41664999.
Wei W. Single-atom nanozymes towards central nervous system diseases. Nano Res. 2023;16(4):4500-4515.
Zhang S et al. Strategies to improve the blood-brain barrier penetration of nanozymes. Theranostics. 2023;13(8):2494-2510.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Research identifies single-atom nanozymes (SAzymes) as a powerful platform for treating CNS diseases by overcoming the blood-brain barrier....
8 months ago

Following regulatory scrutiny from FSSAI regarding promotional representations and lean muscle preservation claims, Dr. Reddy's Laboratories and Nestlé Health Science are currently reviewing the branding and marketing strategy for their joint nutritional supplement Celevida GLP+.
Today

Demanding exhaustive hormonal profiling can inadvertently discourage clinical studies involving females. Methodological standards must align with the specific scientific question to expand, not restrict, equitable evidence for women.
Today

The Directorate General of Health Services directs Indian states to halt the hazardous reuse and reprocessing of single-use medical devices. Discover regulatory implications under the Drugs and Cosmetics Act, critical infection risks, legal liabilities, and operational changes required across clinical specialties.
Today

A novel calcium polyphosphate coacervate enables injectable bone implants with in situ hierarchical porosity via phase separation and gas foaming, significantly enhancing cell proliferation, energy metabolism, and osteogenic differentiation for minimally invasive bone defect repair.
Today

India is advancing preventive healthcare by integrating genomics, artificial intelligence, and quantum technologies. With the SANGAM programme sequencing one million Indian genomes, clinicians can unlock personalized therapies, detect cardiometabolic risks early, and curb the burden of diabetes and heart disease.
Today